Fuji Pharma Co Ltd

Fuji Pharma maintains a conservative capital structure with a debt-to-equity ratio of 0.66, indicating a balanced approach to financing. The company's liquidity position is characterized as medium, with a current ratio of 1.55, suggesting it can meet short-term obligations but with limited excess cash. However, the firm's net cash position is negative after subtracting total debt, signaling potential refinancing or liquidity management challenges. Profitability metrics show Fuji Pharma's return on equity (ROE) at 6.4%, which is below the typical benchmark for pharmaceutical firms, and its return on assets (ROA) at 3.21%, indicating moderate efficiency in asset utilization. The company's gross margin is 40.2%, and its operating margin is 8.15%, both of which are in line with industry norms but suggest limited pricing power or cost control advantages. Fuji Pharma's revenue is concentrated in Japan, with no disclosed international operations, making it highly sensitive to domestic regulatory and market dynamics. The company does not report segment-level revenue, but its product portfolio includes both generic and branded drugs, with no indication of geographic diversification. Looking ahead, Fuji Pharma's revenue is projected to grow by 3.5% in the current fiscal year and 2.8% in the next, based on analyst estimates and historical performance. The company's free cash flow of 2.08 billion JPY supports reinvestment or shareholder returns, though capital expenditures of -3.85 billion JPY suggest asset disposals or cost reductions. The company faces moderate liquidity risk due to its net cash position and a medium risk of dilution, though the probability of near-term dilution is low. No recent filings or transcripts indicate material changes in strategy or operations, and the firm's risk profile remains stable.